Global patient alliance integrating patient preferences and real-world outcomes into drug development and regulatory research consortia.
IAPO is a global umbrella body that represents patient organizations across multiple countries, bringing the collective patient voice into scientific research, drug development policy, and regulatory decision-making. In H2020 consortia, they contribute structured patient input — lived experience, treatment preferences, and outcome priorities — that academic and pharmaceutical partners cannot generate themselves. Their H2020 work sits at the intersection of patient engagement and regulatory science: one project focused on how patient preferences should formally influence benefit-risk assessments in drug approval, the other on how real-world patient data can validate medicine effectiveness beyond clinical trials. For research consortia, they function as the authoritative channel between scientific teams and the communities of people actually living with the conditions being studied.
The PREFER project (2016-2022) was specifically designed to develop and test methods for capturing patient preferences and incorporating them into drug regulatory benefit-risk decisions.
The GetReal Initiative (2018-2021) focused on integrating real-world evidence into medicine development and HTA processes, with IAPO contributing the patient perspective on what real-world outcomes matter.
Both PREFER and GetReal are IMI-funded or RIA programmes requiring formal patient involvement, and IAPO's participation in both signals they are a go-to partner for satisfying that requirement credibly.
As a global patient alliance, IAPO brings policy-level legitimacy and access to patient networks across conditions and geographies, supporting dissemination and stakeholder engagement in both projects.
With only two projects across 2016-2018, the evolution is narrow but directional. Their first engagement (PREFER, 2016) focused upstream — on systematically measuring patient preferences to shape regulatory benefit-risk frameworks before a medicine is approved. Their second project (GetReal, 2018) moved downstream — toward how real-world evidence from actual clinical practice can inform drug evaluation and HTA decisions after approval. Both themes are connected by a single logic: making medicine development and regulation more reflective of how patients experience disease and treatment in real life, not just in controlled trials.
IAPO appears to be deepening its role in the methodological foundations of patient-centered regulatory science — moving from preference elicitation toward real-world evidence generation — a direction directly aligned with growing EMA and HTA body demands for post-market patient-reported data.
IAPO participates exclusively as a consortium partner, never as coordinator — consistent with their function as a specialist voice rather than a research executor. Despite only two projects, they accumulated 42 unique consortium partners across 9 countries, which signals involvement in large, heavily cross-sector IMI-style consortia that bring together pharma companies, academic institutions, regulators, and patient groups. This pattern suggests they are actively recruited by large consortia that need credible, internationally recognized patient representation rather than a generic community advisory group.
IAPO built a network of 42 unique partners across 9 countries from just two projects, reflecting their involvement in large, multi-stakeholder programmes where broad consortia are the norm. Their connections are concentrated in the health and pharma ecosystem — academic medical centers, regulatory bodies, and pharmaceutical companies — with a predominantly European geographic footprint despite their global mandate.
IAPO is not a disease-specific patient group — they represent patients across conditions and countries, which gives them a breadth of voice that single-disease organizations cannot offer in cross-condition or methods-focused research. For consortium builders in regulated health research, this means one partnership satisfies patient engagement obligations while bringing genuine international reach and policy credibility. Their track record in IMI-funded programmes — the most demanding public-private research environment in European health — signals they can operate effectively in complex, multi-partner scientific settings.
